Q2 2010 Nektar Therapeutics Financial Results Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Jim Tumbrink - BMO Capital Markets - Analyst : Hi, thanks. It's Jim Tumbrink here with Burt. Thanks for taking the question. Howard, I know you said enrollment in the extension study for ovarian cancer is going well. Just wondering if you can put any numbers behind that? Secondly, on a partnership, now that you're focusing on the potential filing, assuming that study goes well, have you changed your thinking around the terms or how much you might like to retain for yourself of that compound.

Question: John Sonnier - William Blair & Company - Analyst : Thanks for taking the question, and congrats on a lot of progress over there. Howard, I appreciate the update on this 50-patient extension study with 102. I think what would be helpful is, talk a little bit about, maybe, Lorianne, what the doxil NDA package hooked like back in 2002, and compare that to 102. So you finished the extension study. What will that body of data look like, how many patients, and how does that compare to what doxil got approved on? Thanks.

Question: John Sonnier - William Blair & Company - Analyst : I guess more than the clinical response, I'm trying to get a sense of what the respective data packages look like from the standpoint of patient numbers, the number of trials, et cetera, because that's the pushback I get sometimes, is that you won't have enough data on the extension study to file.

Question: John Sonnier - William Blair & Company - Analyst : Okay. Thank you.

Question: Ian Sanderson - Cowen & Co - Analyst : Good afternoon. Thanks for taking the question. Just a follow-up on that same line of questioning, will the expansion programs for NKTR-102 yield any survival data, or are you planning to try to go forward here with PFS results?

Question: Ian Sanderson - Cowen & Co - Analyst : Okay. And could you update us on the status of PEG [Advy]?

Question: Ian Sanderson - Cowen & Co - Analyst : This was for Baxter's. PEGylated Advy. Is that still in development?

Question: Ian Sanderson - Cowen & Co - Analyst : Is anything in the clinic at this point, or is it still pre-clinical formulation?

Question: Ian Sanderson - Cowen & Co - Analyst : Okay. Thank you very much.

Question: Pamela Bassett - Cantor Fitzgerald - Analyst : Hi, everybody. Will you talk about how you might proceed with 181 from a clinical development standpoint? I'm assuming that this could move forward rather quickly.

Question: Pamela Bassett - Cantor Fitzgerald - Analyst : Howard, could that compound move into position number three from a partnering standpoint?

Question: Pamela Bassett - Cantor Fitzgerald - Analyst : But, say, next year after you've had some Phase I results, will you be able to correlate the animal models?

Question: Pamela Bassett - Cantor Fitzgerald - Analyst : Great. Thanks.